Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

On March 27, 2026 Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, reported it will host its March Stakeholder Webcast focused on continued progress of its botensilimab and balstilimab (BOT+BAL) immunotherapy program and will provide an update on the Company’s patient access programs, development across tumor types, and key priorities for 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The session will be moderated by Garo H. Armen, PhD, Founder, Chairman, and Chief Executive Officer of Agenus, and will conclude with a live Q&A.

Featured Topics and Speakers

Strategic Direction: Advancing BOT+BAL
Garo Armen, PhD
Founder, Chairman, and Chief Executive Officer, Agenus
Dr. Armen will open the session by discussing Agenus’ mission to harness the immune system across tumor types and the urgency of advancing new options for patients with historically treatment-resistant cancers. He will also outline key priorities for 2026 as momentum continues to build across the BOT+BAL program.

Clinical Progress: Durability and Consistency Across Tumors
Steven J. O’Day, MD
Chief Medical Officer, Agenus
Dr. O’Day will provide a clinical perspective on the durability and consistency of BOT+BAL across tumor types, including in historically immunotherapy-resistant cancers. He will also highlight how these data are informing ongoing development and later-stage trials.

Access and Execution: Expanding Patient Through Available Global Programs
Kamel Djazouli, MD
Head, Medical Affairs, Agenus
Dr. Djazouli will provide an update on Agenus’ global access programs, including the France AAC and Named Patient Programs, and how they are enabling treatment for patients with limited options.
Stakeholder Briefing Details:

Registration Link: View Source
Live webcast link will be provided once registration is completed.

Submit questions in advance at: View Source

This session marks the second event in Agenus’ 2026 Stakeholder Briefing Series, building on prior discussions regarding BOT+BAL’s clinical progress, patient access pathways, and Agenus corporate milestones.

(Press release, Agenus, MAR 27, 2026, View Source;BAL-Across-Tumor-Types-and-Expand-Patient-Access/default.aspx [SID1234663984])